Hospitalized COVID-19 patients at high risk for becoming critically ill and dying had significantly better outcomes if they received the anti-inflammatory drug anakinra, researchers have found.
"The clinical benefit with anakinra treatment was already apparent from day 14, and this is of clinical importance because the first 14 days is the period during which a patient is expected to worsen. Anakinra benefit was maintained until day 28," they said. In test tube experiments described on Wednesday in Science Advances, researchers found that anticoagulants used after coronary stenting - clopidogrel, sold as Plavix by Bristol Myers Squibb and Sanofi, and ticagrelor, sold as Brilinta by AstraZeneca - keep COVID-19 patients' platelets from becoming over-activated by blocking the P2Y12 protein on their surface.
In test tube experiments, researchers found that Mu is "highly resistant" to antibodies in blood samples from COVID-19 survivors and from people who got the mRNA vaccine from Pfizer and BioNTech. Nevertheless, study coauthor Kei Sato of the University of Tokyo said understanding how variations in spike proteins affect the potency of neutralization antibodies is important for developing new vaccines and predicting breakthrough infections.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: manilabulletin - 🏆 25. / 51 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: ABSCBNNews - 🏆 5. / 83 Read more »
Source: TheManilaTimes - 🏆 2. / 92 Read more »
Source: ANCALERTS - 🏆 26. / 50 Read more »
Ilocos provinces seek more vaccine allocations amid COVID-19 surgeThe provinces of Ilocos Norte and Ilocos Sur are clamoring for higher allocation of COVID-19 vaccines amid rising hospitalizations and deaths fueled by the highly transmissible variants of COVID-19, local officials said. | jmichaelmgsINQ jmichaelmgsINQ state of calamity din ang bunganga no harry...sana tahiin!!
Source: inquirerdotnet - 🏆 3. / 86 Read more »